Exhibit 99.3

 

Unaudited Pro Forma Condensed Combined Balance Sheet

NextPlat Corp and Progressive Care Inc.

June 30, 2023

 

   

NextPlat

   

Progressive

   

Pro Forma

     

Pro Forma

 
   

Corp

   

Care, Inc.

   

Adjustments

 

Reference

 

Combined

 
                                   

ASSETS

                                 

Current Assets

                                 

Cash

  $ 20,605,670     $ 7,352,183     $ -  

A

  $ 27,957,853  

Accounts receivable, net

    589,119       4,951,408                 5,540,527  

Other receivables, net

    -       1,526,756                 1,526,756  

Inventory

    2,066,214       1,630,881                 3,697,095  

Unbilled revenue

    175,410       -                 175,410  

VAT receivable

    432,777       -                 432,777  

Prepaid expenses – current portion

    347,341       220,314                 567,655  

Total Current Assets

    24,216,531       15,681,542                 39,898,073  
                                   

Property and equipment, net

    1,032,006       2,720,471       1,244,789  

D

    4,997,266  
                                   

Other Assets

                                 

Goodwill

    -       1,387,860       (1,387,860 )

E

    -  
                      2,465,000  

E

    2,465,000  

Operating right-of-use assets, net

    756,819       368,270                 1,125,089  

Finance right-of-use assets, net

    -       37,143                 37,143  

Intangible assets, net

    37,500       102,327       14,720,000  

D

    14,859,827  

Equity method investment

    4,820,888       -       506,000  

A

       
                      1,439,637  

C

       
                      (6,766,525 )

C, F

    -  

Prepaid expenses – long term portion

    49,373       -                 49,373  

Deposits

    -       39,137                 39,137  

Total Other Assets

    5,664,580       1,934,737       10,976,252         18,575,569  

Total Assets

  $ 30,913,117     $ 20,336,750       12,221,041       $ 63,470,908  
                                   

LIABILITIES AND STOCKHOLDERS’ EQUITY

                                 
                                   

Current Liabilities

                                 

Accounts payable and accrued expenses

  $ 1,284,470     $ 8,196,322               $ 9,480,792  

Contract liabilities

    58,873       -                 58,873  

Notes payable and accrued interest

    -       148,181                 148,181  

Note payable Coronavirus loans– current portion

    63,171       -                 63,171  

Due to related party

    20,000       -                 20,000  

Operating lease liabilities - current

    204,465       184,378                 388,843  

Finance lease liabilities - current

    -       23,816                 23,816  

Income taxes payable

    160,974       -                 160,974  

Total Current Liabilities

    1,791,953       8,552,697                 10,344,650  
                                   

Long Term Liabilities:

                                 

Notes payable - long term

    -       1,173,364                 1,173,364  

Notes payable Coronavirus – long term

    131,607       -                 131,607  

Operating lease liabilities – long term

    567,071       215,203                 782,274  

Finance lease liabilities - long term

    -       14,735                 14,735  

Total Liabilities

    2,490,631       9,955,999                 12,446,630  
                                   

Stockholders' Equity

                                 

Preferred stock

    -       3                 3  

Common stock

    1,870       67,131       (67,131 )

A

    1,870  

Additional paid-in capital

    65,171,061       30,055,095       506,000  

A

    90,169,691  
                      (21,527,254 )

E

       
                      15,964,789  

D

       

Accumulated deficit

    (36,674,775 )     (19,741,478 )     1,439,637  

C

    (54,976,616 )

Accumulated other comprehensive loss

    (75,670 )     -                 (75,670 )

Total stockholders' equity

    28,422,486       10,380,751       (3,683,959 )       35,119,278  
                                   

Non-controlling interest

                    15,905,000  

E

    15,905,000  
                                   

Total Liabilities and Stockholders' Equity

  $ 30,913,117     $ 20,336,750     $ 12,221,041       $ 63,470,908  
                                   

Book value per share

  $ 1.52     $ 2.00               $ 1.88  
                                   

Shares of common stock outstanding

    18,699,596       5,188,033                 18,699,596  

 

F-1

Unaudited Pro Forma Condensed Combined Statement of Operations

NextPlat Corp and Progressive Care Inc.

Six months ended June 30, 2023

 

   

NextPlat

   

Progressive

   

Pro Forma

     

Pro Forma

 
   

Corp

   

Care, Inc.

   

Adjustments

 

Reference

 

Combined

 
                                   

Net sales

  $ 5,833,515     $ 22,948,029               $ 28,781,544  
                                   

Cost of sales

    4,368,830       16,242,498                 20,611,328  
                                   

Gross profit

    1,464,685       6,705,531       -         8,170,216  
                                   

Operating expenses:

                                 

Selling, general and administrative

    6,058,554       6,046,464       (115,000 )

G

    11,990,018  

Bad debt expense

    -       21,100                 21,100  

Total operating expenses

    6,058,554       6,067,564       (115,000 )       12,011,118  
                                   

Income (Loss) before other (income) expense

    (4,593,869 )     637,967       115,000         (3,840,902 )
                                   

Other (income) expense:

                                 

Interest expense

    9,708       214,640                 224,348  

Debt conversion expense

    -       5,205,609                 5,205,609  

Interest income

    (182,748 )     (12,417 )               (195,165 )

Gain on sale or disposal of property and equipment

    -       (2,500 )               (2,500 )

Other income

    (315,845 )     -       115,000  

G

    (200,845 )

Foreign currency exchange rate variance

    (68,673 )     -                 (68,673 )

Total other (income) expense

    (557,558 )     5,405,332       -         4,962,774  
                                   

Loss before income taxes

    (4,036,311 )     (4,767,365 )               (8,803,676 )
                                   

Income taxes

    (52,023 )     -                 (52,023 )

Loss before equity method investment

    (4,088,334 )     (4,767,365 )     -         (8,855,699 )
                                   

Equity in net loss of affiliate

    (1,439,637 )     -       1,439,637  

F

    -  

Net loss

  $ (5,527,971 )   $ (4,767,365 )     1,439,637       $ (8,855,699 )

 

F-2

 

Unaudited Pro Forma Condensed Combined Statement of Operations

NextPlat Corp and Progressive Care Inc.

Year Ended December 31, 2022

 

   

NextPlat

   

Progressive

   

Pro Forma

     

Pro Forma

 
   

Corp

   

Care, Inc.

   

Adjustments

 

Reference

 

Combined

 
                                   

Net sales

  $ 11,710,142     $ 40,601,859               $ 52,312,001  
                                   

Cost of sales

    9,221,294       30,898,783                 40,120,077  
                                   

Gross profit

    2,488,848       9,703,076                 12,191,924  
                                   

Operating expenses:

                                 

Selling, general and administrative

    9,690,631       12,285,174                 21,975,805  

Bad debt expense

    -       (3,300 )               (3,300 )

Total operating expenses

    9,690,631       12,281,874                 21,972,505  
                                   

Income (Loss) before other (income) expense

    (7,201,783 )     (2,578,798 )               (9,780,581 )
                                   

Other (income) expense:

                                 

Change in fair value of derivative liabilities

    -       3,322,500                 3,322,500  

Gain on debt extinguishment

    -       (953,228 )               (953,228 )

Grant revenue

    -       (2,079,297 )               (2,079,297 )

Other finance costs

    -       147,622                 147,622  

Abandoned offering costs

    -       635,545                 635,545  

Day one loss on issuance of units

    -       1,026,155                 1,026,155  

Day one loss on debt modification

    -       523,526                 523,526  

Interest expense

    24,497       797,715                 822,212  

Interest income

    (20,814 )     (84,742 )               (105,556 )

Gain on sale or disposal of property and equipment

    -       (11,562 )               (11,562 )

Other income

    -       -                 -  

Foreign currency exchange rate variance

    128,648       -                 128,648  

Total other (income) expense

    132,331       3,324,234                 3,456,565  
                                   

Loss before income taxes

    (7,334,114 )     (5,903,032 )               (13,237,146 )
                                   

Income taxes

    (87,000 )     (866 )               (87,866 )

Loss before equity method investment

    (7,421,114 )     (5,903,898 )               (13,325,012 )
                                   

Equity in net loss of affiliate

    (1,739,475 )     -       1,739,475  

F

    -  

Net loss

  $ (9,160,589 )   $ (5,903,898 )     1,739,475       $ (13,325,012 )

Series A Preferred Stock dividend associated with induced conversion

    -       (541,278 )     -         (541,278 )

Net loss attributable to Common Shareholders

  $ (9,160,589 )   $ (6,445,176 )     1,739,475       $ (13,866,290 )

 

 

F-3

 

NEXTPLAT CORP AND SUBSIDIARIES

Unaudited Pro Forma Condensed Combined Financial Statements

 

Note 1. Basis of Presentation

 

The accompanying Unaudited Pro Forma Condensed Combined Financial Statements (the “Pro Forma Statements”) present the proforma combined financial position and results of operations of the combined company based upon the historical consolidated financial statements of NextPlat Corp (“NextPlat” or the “Company”) and the historical consolidated financial statements of Progressive Care Inc. (“Progressive Care”), after giving effect to the Acquisition and adjustments described in these footnotes, and are intended to reflect the impact of the Acquisition on NextPlat.

 

On August 30, 2022, NextPlat entered into a Securities Purchase Agreement (the “SPA”) between NextPlat and Progressive Care, under which NextPlat, its Executive Chairman and Chief Executive Officer, Charles M. Fernandez, board member, Rodney Barreto, and certain other investors invested an aggregate of $8.3 million into Progressive Care.  In connection with the SPA, NextPlat purchased 3,000 newly issued Units of Progressive Care valued at $6 million, with each Unit comprised of one share of Progressive Care’s Series B Convertible Preferred Stock, $0.001 par value,  and one Investor Warrant to purchase a share of Series B Convertible Preferred Stock at an exercise price of $2,000  The Investor Warrants may also be exercised, in whole or in part, by means of a cashless exercise.  The Convertible Preferred Stock has a stated value of $2,000 per share and each Preferred Stock share has the equivalent voting rights of 500 common stock shares (after giving effect to the Reverse Stock Split described below).  Each share of Series B Convertible Preferred Stock is convertible at any time at the option of the holder into shares of  Progressive Care Common Stock shares determined by dividing the stated value by the conversion price which is $4.00 (after giving effect to the Reverse Stock Split described below).  

 

In addition, on August 30, 2022, NextPlat Corp, Messrs. Fernandez and Barreto, and certain other investors (collectively, the “NextPlat Investors”) entered into a Modification Agreement wherein the terms were modified for an existing Secured Convertible Promissory Note (the “Note”) originally held by a third party note holder and sold to the NextPlat Investors.  The NextPlat Investors purchased the Note as part of a Confidential Note Purchase and Release Agreement between the former note holder and the NextPlat Investors.  As of the date of the SPA, the aggregate amount of principal and interest outstanding on the Note was approximately $2.8 million.  As part of the Modification Agreement, various terms of the Note were modified, among them, the Conversion Price for the Note was modified to a fixed price of $4.00 per share of common stock (after giving effect to the Reverse Stock Split described below).  In addition, the Note was modified to provide for mandatory conversion upon the later to occur of (a) the completion of the Company’s reverse stock split, and (b) the listing of the Company’s common stock on a national exchange, including the Nasdaq Capital Market, the Nasdaq Global Market, or the New York Stock Exchange. Also, pursuant to the SPA, Messrs. Fernandez and Barreto were nominated for election to Progressive Care’s Board of Directors.  

 

On September 13, 2022, the Progressive Care Board of Directors appointed Charles M. Fernandez as Chairman of the Board of Directors and Rodney Barreto as the Vice Chairman of the Board of Directors. In connection with these appointments, Alan Jay Weisberg, Progressive Care’s current Chairman and Chief Executive Officer, was appointed to serve as a Vice Chairman. On September 12, 2022, two of Progressive Care’s Directors, Birute Norkute and Oleg Firer, resigned as Directors. On October 7, 2022, the Progressive Care Board of Directors unanimously voted to approve the appointment of Pedro Rodriguez, MD to the Board.  Dr. Rodriguez was nominated to the Progressive Care Board by NextPlat.

 

On November 11, 2022, Mr. Weisberg resigned from his positions as Progressive Care’s Chief Executive Officer and co-Vice-Chairman of the Board of Directors.  On the same date, the Board appointed Mr. Fernandez to serve as the new Chief Executive Officer immediately.  

 

On December 29, 2022, Progressive Care filed a Certificate of Amendment to Articles of Incorporation (the “Amendment to Articles”) with the Secretary of State of the State of Delaware. Pursuant to the Amendment to Articles, each 200 shares of Progressive Care’s common stock outstanding was converted into one share of common stock (the “Reverse Stock Split”) and the number of shares of common stock that Progressive Care is authorized to issue was reduced to 100 million (the “Reduction in Authorized Stock”). The Reverse Stock Split and the Reduction in Authorized Stock were approved by the Progressive Care Board of Directors and the shareholders.

 

F-4

 

On May 5, 2023, NextPlat entered into a Securities Purchase Agreement (the “SPA”) with Progressive Care,  pursuant to which NextPlat purchased 455,000 newly issued units of securities from Progressive Care (the “Units”) at a price per Unit of $2.20 for an aggregate purchase price of $1 million (the “Unit Purchase”). Each Unit consisted of one share of common stock, par value $0.0001 per share, of Progressive Care and one warrant to purchase a share of common stock (the “PIPE Warrants”). The PIPE Warrants have a three-year term and are immediately exercisable. Each PIPE Warrant is exercisable at $2.20 per share of common stock. On May 9, 2023, the Companies closed the transactions contemplated in the SPA. Progressive Care received cash proceeds of $880,000, net of placement agent commission of $70,000 and legal fees of $50,000.

 

Simultaneous with the closing, Progressive Care entered into a Debt Conversion Agreement (the “DCA”) with NextPlat and the other holders (the “Holders”) of that certain Amended and Restated Secured Convertible Promissory Note, dated as of September 2, 2022, made by the Company in the original face amount of approximately $2.8 million (the “Note”). Pursuant to the DCA, NextPlat and the other Holders agreed to convert the total approximately $2.9 million of outstanding principal and accrued and unpaid interest to Common Stock at a conversion price of $2.20 per share (the “Debt Conversion”). Of the total 1,312,379 shares of Common Stock issued upon conversion of the Note pursuant to the DCA, NextPlat received 570,599 shares, Charles M. Fernandez, the Company’s Chairman and Chief Executive Officer, received 228,240 shares, and Rodney Barreto, the Company’s Vice-Chairman of the Board of Directors, received 228,240 shares. In addition, each of the Holders also received a warrant to purchase one share of Common Stock for each share of Common Stock they received upon conversion of the Note (the “Conversion Warrants”). The Conversion Warrants have a three-year term and are immediately exercisable. Each Conversion Warrant is exercisable at $2.20 per share of Common Stock. In addition, the Company issued 330,000 warrants to certain existing Progressive Care investors to induce them to approve the transaction contemplated by the SPA (the “Inducement Warrants”). Charles M. Fernandez and Rodney Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Common Stock, respectively. The Inducement Warrants have a three-year term and are immediately exercisable. Each Inducement Warrant is exercisable at $2.20 per share of Common Stock.

 

On July 1, 2023, NextPlat, along with Messrs. Fernandez and Barreto, exercised common stock purchase warrants and were issued common stock shares by Progressive Care. NextPlat exercised common stock purchase warrants on a cashless basis and was issued 402,269 common stock shares. NextPlat also exercised common stock purchase warrants on a cash basis and paid consideration in the amount of $506,000 and was issued 230,000 common stock shares. Mr. Fernandez exercised common stock purchase warrants on a cashless basis and was issued 211,470 common stock shares. Mr. Barreto exercised common stock purchase warrants on a cashless basis and was issued 130,571 common stock shares. After the exercise of the common stock purchase warrants, NextPlat, Messrs. Fernandez and Barreto collectively owned approximately 53% of the Company’s voting common stock. As of June 30, 2023, prior to the exercise of the common stock purchase warrants, NextPlat and Messrs. Fernandez and Barreto collectively owned approximately 46% of the Company’s voting common stock.

 

Also, on June 30, 2023, NextPlat, along with Messrs. Fernandez and Barreto, entered into a voting agreement whereby at any annual or special shareholders meeting of Progressive Care’s stockholders, and whenever the holders of Progressive Care’s common stock act by written consent, Messrs. Fernandez and Barreto agreed to vote all of the common stock shares (including any new shares acquired after the date of the voting agreement or acquired through the conversion of securities convertible into Common Stock) that they own, directly or indirectly, in the same manner that NextPlat votes its common stock and equivalents. The voting agreement is irrevocable and perpetual in term.

 

As a result of the common stock purchase warrant exercises and the entry into the voting agreement, NextPlat concluded that there was a change in control in Progressive Care under the voting interest model in U.S. GAAP. As of July 1, 2023, NextPlat has the right to control more than 50 percent of the voting interest in Progressive Care through the concurrent common stock purchase warrant exercises and voting agreement noted above.

 

The accompanying Pro Forma Statements are presented for illustrative purposes only and do not give effect to any cost savings, revenue synergies or restructuring costs which may result from the integration of NextPlat’s and Progressive Care’s operations. The accompanying Pro Forma Statements have been adjusted to reflect adjustments to NextPlat’s historical consolidated financial information that are (i) directly attributable to the Acquisition, (ii) factually supportable and (iii) to reclassify certain Progressive Care items to conform to NextPlat’s presentation. The Unaudited Pro Forma Combined Statements of Operations reflect the Acquisition as if it had been completed on January 1, 2022. The Unaudited Pro Forma Condensed Combined Balance Sheet reflects the Acquisition as if it was completed on January 1, 2023.

 

F-5

 

Note 2.  Preliminary Purchase Price Allocation

 

The Company has performed a preliminary valuation analysis of the fair market value of the net assets acquired in the Acquisition.  The following table summarizes the preliminary allocation of the purchase price as of the date of the Acquisition.  The purchase price consists of the fair market value of Progressive Care’s net assets as of July 1, 2023.

 

 

      Preliminary Allocation  

Total purchase consideration

  $ 11,517,000  

Fair value of non-controlling interest

    15,905,000  

Total consideration

  $ 27,422,000  
         
         

Identifiable net assets acquired:

       

Cash

  $ 7,352,000  

Accounts receivable, net

    6,478,000  

Inventory

    1,631,000  

Prepaid expenses

    220,000  

Property and equipment, net

    3,965,000  

Right of use assets, net

    405,000  

Intangible assets, net:

       

Trade name

    4,060,000  

Development technology

    2,560,000  

Pharmacy records

    8,100,000  

Other

    102,000  

Deposits

    39,000  

Accounts payable and accrued expenses

    (8,196,000 )

Notes payable and accrued interest - current portion

    (148,000 )

Lease liabilities - current portion

    (208,000 )

Notes payable - long term

    (1,173,000 )

Lease liabilities - long term

    (230,000 )

Net assets acquired

  $ 24,957,000  
         

Goodwill

    2,465,000  

 

The preliminary purchase price allocation has been used to prepare pro forma adjustments in the pro forma condensed combined statement of operations. The final purchase price allocation is subject to change as more detailed analyses are completed and additional information about the fair value of assets acquired becomes available during the measurement period.

 

F-6

 

Note 3. Pro Forma Adjustments

 

The pro forma adjustments are based on the Company’s preliminary estimates and assumptions that are subject to change. The following adjustments have been reflected in the unaudited pro forma condensed combined financial information:

 

 

A.

Adjustment to cash for exercise of common stock purchase warrants to acquire 230,000 shares of Progressive Care common stock on July 1, 2023.

 

 

B.

Adjustment to Progressive Care’s stockholders’ equity for cashless exercise of common stock purchase warrants to acquire Progressive Care common stock on July 1, 2023 as follows:

 

NextPlat Corp                         402,269 shares

 

Charles M. Fernandez             211,470 shares

 

Rodney Barreto                       130,571 shares

 

 

C.

To record elimination of NextPlat equity in earnings of equity method investee (Progressive Care).

 

 

D.

To record adjustment for fair value measurement of previously-held equity interest (PHEI) in Progressive Care in accordance with FASB ASC 805-10-25-10.

 

 

E.

To record purchase price allocation to net assets of Progressive Care, to record fair value of non-controlling interest, and to record goodwill for value obtained in excess of net assets acquired.

 

Purchase price allocation:

       

Consideration paid

  $ 11,517,000  

Fair-value of non-controlling interest

    15,905,000  
    $ 27,422,000  
         

Allocated to:

       

Historical book value of Progressive Care, Inc. assets and liabilities

  $ 10,381,000  

Elimination of Progressive Care, Inc. purchased goodwill

    (1,388,000 )

Fair value adjustments:

       

Trade name

    4,060,000  

Developed technology

    2,560,000  

Pharmacy records

    8,100,000  

Building & other intangibles

    1,244,000  

Goodwill

    2,465,000  
    $ -  

 

 

F.

To record elimination of NextPlat equity in net loss of affiliate (Progressive Care).

 

 

G.

To eliminate intercompany management service income and expense.  

 

F-7